8-K: Axogen Reports Strong Q4 and Full-Year 2023 Results, Anticipates Continued Growth

Axogen reported an 18.7% increase in fourth-quarter revenue and a 14.7% increase in full-year revenue for 2023, driven by growth in both trauma and non-trauma procedures.

Summary

• Axogen's fourth-quarter revenue reached $42.9 million, an 18.7% increase compared to the same period in 2022.
• Approximately half of the fourth-quarter revenue came from emergent trauma procedures, which grew by mid-single digits year-over-year.
• The other half of the revenue was from scheduled non-trauma procedures, which saw growth of more than 25% compared to the fourth quarter of 2022.
• The company's gross margin for the fourth quarter was 78.7%, down from 83.0% in the fourth quarter of 2022.
• Axogen reported a net loss of $3.9 million, or $0.09 per share, for the fourth quarter, an improvement from a net loss of $5.4 million, or $0.13 per share, in the same period of 2022.
• Adjusted net loss for the quarter was $2.6 million, or $0.06 per share, compared to an adjusted net loss of $1.1 million, or $0.03 per share in the fourth quarter of 2022.
• Adjusted EBITDA for the quarter was $0.6 million, compared to an adjusted EBITDA loss of $0.7 million in the fourth quarter of 2022.
• Full-year 2023 revenue was $159.0 million, a 14.7% increase compared to $138.6 million in 2022.
• Core accounts contributed approximately 65% of the total revenue.
• The full-year gross margin was 80.4%, compared to 82.6% in 2022.
• The net loss for the full year was $21.7 million, or $0.51 per share, compared to a net loss of $28.9 million, or $0.69 per share in 2022.
• Adjusted net loss for the full year was $7.3 million, or $0.17 per share, compared to $12.6 million, or $0.30 per share in 2022.
• Adjusted EBITDA loss for the full year was $1.1 million, compared to an adjusted EBITDA loss of $9.3 million in 2022.
• The company ended the year with 376 core accounts, a 13.3% increase from the previous year.
• Axogen anticipates completing the BLA submission in the third quarter of 2024, with potential approval in mid-2025.
• The company expects 2024 revenue to be between $177 million and $181 million, representing an annual growth rate of approximately 11% to 14%.
• The company anticipates a full-year gross margin between 76% and 79%.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved profitability, and a clear path for future product launches and regulatory approvals. While there are some challenges, the overall tone is optimistic and suggests a positive trajectory for the company.

Positives

• Axogen experienced significant revenue growth in both the fourth quarter and full year of 2023.
• The company saw strong growth in scheduled non-trauma procedures, indicating increased adoption of their products in elective surgeries.
• Axogen improved its profitability, moving from an adjusted EBITDA loss to a positive adjusted EBITDA in the fourth quarter.
• The company reduced its full-year adjusted EBITDA loss significantly compared to the previous year.
• Axogen has a clear timeline for the BLA submission and potential approval, indicating progress in regulatory milestones.
• The company's 2024 revenue guidance suggests continued growth and market expansion.
• The company has expanded its manufacturing capacity with a new biologics processing facility.
• Axogen has a growing body of clinical evidence supporting its products, with 245 peer-reviewed publications.

Negatives

• The company's gross margin decreased in both the fourth quarter and full year of 2023 compared to the previous year.
• Axogen reported a net loss for both the fourth quarter and full year, although the losses were reduced compared to 2022.
• The company's adjusted net loss increased in the fourth quarter compared to the same period in 2022.

Risks

• The company's future performance is subject to various factors, including global supply chain issues and hospital staffing challenges.
• Regulatory approvals are not guaranteed and may be subject to delays.
• The company's financial performance is subject to market conditions and competition.
• The company's ability to achieve its revenue guidance depends on the adoption of its products by surgeons and healthcare providers.
• Geopolitical conflicts and global business disruptions could impact the company's operations and financial results.

Future Outlook

Axogen expects 2024 revenue to be in the range of $177 million to $181 million, representing an annual growth rate of approximately 11% to 14%, and anticipates a full-year gross margin between 76% and 79%.

Management Comments

• Karen Zaderej, chairman, CEO, and president of Axogen, Inc., stated that they are pleased with their solid performance in the fourth quarter and encouraged by the continued momentum in the first quarter.
• Ms. Zaderej also mentioned that they remain focused on further penetrating core accounts by leveraging their growing body of clinical evidence and expanding use cases with their innovative new products and applications.

Industry Context

Axogen is a leader in the peripheral nerve repair market, and this announcement highlights their continued growth and innovation in this space. The company's focus on both trauma and non-trauma procedures positions them well to capture a significant share of the market. The launch of new products and the expansion of their clinical evidence base are key factors in their competitive strategy.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, Axogen's revenue growth of 14.7% for the full year is a strong indicator of their performance in the medical device industry.
• Companies like Integra LifeSciences and Medtronic, which also operate in the regenerative medicine and surgical solutions space, are potential comparables, but their specific financial results would need to be analyzed for a direct comparison.
• Axogen's gross margin of 80.4% for the full year is relatively high, suggesting a strong pricing power and efficient cost management, but a decrease from 82.6% in 2022 indicates potential cost pressures.
• The company's focus on clinical evidence and product innovation aligns with industry trends towards value-based healthcare and the adoption of advanced medical technologies.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved profitability positively.
• Employees may be encouraged by the company's growth and future prospects.
• Customers, including surgeons and healthcare providers, will benefit from the company's innovative products and solutions.
• Patients will benefit from the company's focus on restoring nerve function and quality of life.

Next Steps

• Axogen will launch Avive+ Soft Tissue Matrix in the second quarter of 2024.
• The company will complete the BLA submission in the third quarter of 2024.
• Axogen will continue to focus on penetrating core accounts and expanding use cases for its products.
• The company will host a conference call and webcast for the investment community to discuss the results.

Key Dates

Keywords

peripheral nerve repair, nerve regeneration, surgical solutions, Avance nerve graft, Axoguard, biologics, trauma procedures, non-trauma procedures, BLA submission, medical devices